Sara Nik
Stock Analyst at H.C. Wainwright
(1.08)
# 3,643
Out of 4,421 analysts
39
Total ratings
20.5%
Success rate
-2.1%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Sara Nik
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KTTA Pasithea Therapeutics | Reiterated: Buy | $3 | $0.5023 | +497.25% | 7 | Jun 16, 2026 | |
| STO: CANTA Cantargia AB (publ) | Reiterated: Buy | kr 14.00 | $2.15 | +551.16% | 8 | Jun 11, 2026 | |
| TVRD Tvardi Therapeutics | Initiated Coverage: Buy | $9 | $2.58 | +248.84% | 1 | Jun 8, 2026 | |
| MBRX Moleculin Biotech | Reiterated: Buy | $22 | $2.80 | +685.71% | 15 | May 15, 2026 | |
| CRIS Curis | Reiterated: Buy | $17 | $0.406 | +4,087.19% | 7 | May 13, 2026 | |
| KAPA Kairos Pharma | Reiterated: Buy | $12 | $0.457 | +2,525.82% | 1 | Aug 13, 2025 |
Pasithea Therapeutics
Jun 16, 2026
Reiterated: Buy
Price Target: $3
Current: $0.5023
Upside: +497.25%
Cantargia AB (publ)
Jun 11, 2026
Reiterated: Buy
Price Target: kr 14.00
Current: $2.15
Upside: +551.16%
Tvardi Therapeutics
Jun 8, 2026
Initiated Coverage: Buy
Price Target: $9
Current: $2.58
Upside: +248.84%
Moleculin Biotech
May 15, 2026
Reiterated: Buy
Price Target: $22
Current: $2.80
Upside: +685.71%
Curis
May 13, 2026
Reiterated: Buy
Price Target: $17
Current: $0.406
Upside: +4,087.19%
Kairos Pharma
Aug 13, 2025
Reiterated: Buy
Price Target: $12
Current: $0.457
Upside: +2,525.82%